-
Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary InterventionJD McClure, JC Ramsay , C Berry et al. -
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS TrialSS Anand, JW Eikelboom, COMPASS Trial Investigators.
-
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registrySahlén A, Varenhorst C, Lagerqvist B et al.
-
Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery diseaseYiY Zheng, TT Wu, X Xie et al.
-
Antibody-Based Ticagrelor Reversal Agent in Healthy VolunteersDL Bhatt, CV Pollack, JS Lee et al.
-
Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE TrialY Park, JH Kim, TH Kim et al.
-
Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGYU Baber, R Chandiramani, R Mehran et al.
-
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert PanelD Capodanno, MC Morice, DJ Angiolillo et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
